Genmab — Juli 2020
-
and i forgot earlier, i expect we hear something by August about what Genmab wants to do with Cami-t https://twitter.com/adctherapeutics/status/1285589645275865088
-
Og vi kan nok godt risikere, at det fortsætter nedad med dollarkursen https://edition.cnn.com/2020/07/16/investing/us-dollar-coronavirus-trump/index.html
-
God morgen.
-
FDA approval sought for Selinexor in Myeloma after 1 prior line of therapy. https://www.onclive.com/view/fda-approval-sought-for-selinexor-in-myeloma-after-1-prior-line-of-therapy?eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==
-
Genmab i rekord får lagt 18,5 pct. til kursmålet hos Bernstein
06:40
Det amerikanske finanshus Bernstein har løftet sit kursmål for Genmab med 18,5 pct. til 2275 kr. fra 1920 kr.Samtidig holdes der fast i den positive anbefaling outperform, fremgår det af data fra Bloomberg News.
Genmab-aktien er - ligesom store dele af det danske marked - inde i en god periode lige nu, og tirsdag sluttede aktien atter i rekord, da den steg med 0,1 pct. til 2340 kr.
-
Transcript of Novartis earnings call https://finance.yahoo.com/news/edited-transcript-novn-earnings-conference-214116224.html When you look at our late-stage pipeline, just to go through some of the key assets in detail, ofatumumab, we continue to have very good discussions with FDA. We're on track for our action date in September of 2020, no major issues. And happy to, of course, answer any questions, but we feel very good about where we are in that discussion and the ongoing label negotiation.
-
It´s ok to do it.
-
Then we will have the information in the chat-history.
-
we're very much looking forward to bringing ofatumumab to market. And we believe the FDA now has all the data they need to give us the green light. What is most compelling about ofatumumab is that it can give patients the possibility to live relapse-free for 9 to 10 years. What ofatumumab does is it effectively depletes B cells. This is the most efficacious way to treat MS. We've also developed this product specifically for MS with a favorable safety.
-
-
It's also dosed precisely to sustain B cell depletion and it comes in a subcu injection. This has the potential to truly change how physicians treat MS in first line and first switch. Our focus in these past months has been to make it as easy as possible to prescribe and access this product.
-
We've invested significantly in patient services and are rethinking our onboarding to make it seamless and flexible. Our launch will be tailored in a very different environment but with a very different approach, state-by-state, prescriber-by-prescriber. And as soon as we get the green light from FDA, we'll be ready to launch.
-
-Yes. So the timing for ofa was based on, as you remember, the 3-month extension from the FDA. And the timelines currently are in the mid-September time frame. I don't have the exact date, but it's mid-September. And so we're negotiating the aspects of label with FDA. And we expect to reach those timelines, as Vas presented earlier.
-
So we really feel that there's no better time to bring a highly efficacious and safe treatment that can be administered at home to MS patients considering the context. Our initial focus will be to really drive the broad adoption with MS specialists and general neurologists. And we're using a really highly agile approach between face-to-face and virtual outreach. We've actually developed a digital affinity score for physicians to understand where they are and how much digital promotion we can do.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind